Evidence map›Paper›PMID 34034636›Full record

ArticleBioengineered2021

Insulin reverses choriocarcinoma 5- fluorouracil resistance.

Ying Shan, Yanyi Li, Hongyu Han, Cui Jiang, Hu Zhang, Jiachang Hu, Huanmei Sun, Jianglong Zhu

Abstract read
In one paragraph

Article in Bioengineered, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Repurposing metformin for choriocarcinoma: targeting the AMPK/mTOR pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ying ShanDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.
Yanyi LiDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.
Hongyu HanDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.
Cui JiangDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.
Hu ZhangDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.
Jiachang HuDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.
Huanmei SunDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.
Jianglong ZhuDepartment of Obstetrics and Gynecology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Pudong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choriocarcinoma (CC) is a gestational trophoblastic tumor secondary to a gravid or non-gravid pregnancy. It is characterized by rapid growth, high invasion, and high metastatic potential and chemotherapy resistance that significantly affect survival rate of CC patients. Insulin is implicated in alleviation of chemotherapy resistance in CC. However, the mechanism of reversing resistance in CC has not been explored. Our purpose was to explore insulin effect on 5-fluorouracil (5-FU) resistance in CC and elucidate its potential mechanism

Indexed as

ChoriocarcinomaUterine NeoplasmsAnimalsCell Line, TumorDrug Resistance, NeoplasmFemaleFluorouracilHumansInsulinMiceMice, NudePregnancyFluorouracilInsulin5-FUchemoresistanceChoriocarcinomainsulin

Identifiers

PMID34034636
PMCPMC8806519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.